The Highly Potent AhR Agonist Picoberin Modulates Hh-Dependent Osteoblast Differentiation.
Jana FlegelSaad ShaabanZhi Jun JiaBritta SchulteYilong LianAdrian KrzyzanowskiMalte MetzTabea SchneidewindFabian WesselerAnke FlegelAlisa ReichAlexandra BrauseGang XueMinghao ZhangLara DötschIsabelle D StenderJan-Erik HoffmannRebecca ScheelPetra JanningFraydoon RastinejadDennis SchadeCarsten StrohmannAndrey P AntonchickSonja SieversPedro Moura-AlvesSlava ZieglerHerbert WaldmannPublished in: Journal of medicinal chemistry (2022)
Identification and analysis of small molecule bioactivity in target-agnostic cellular assays and monitoring changes in phenotype followed by identification of the biological target are a powerful approach for the identification of novel bioactive chemical matter in particular when the monitored phenotype is disease-related and physiologically relevant. Profiling methods that enable the unbiased analysis of compound-perturbed states can suggest mechanisms of action or even targets for bioactive small molecules and may yield novel insights into biology. Here we report the enantioselective synthesis of natural-product-inspired 8-oxotetrahydroprotoberberines and the identification of Picoberin, a low picomolar inhibitor of Hedgehog (Hh)-induced osteoblast differentiation. Global transcriptome and proteome profiling revealed the aryl hydrocarbon receptor (AhR) as the molecular target of this compound and identified a cross talk between Hh and AhR signaling during osteoblast differentiation.